TechBooky AI Assistant
TechBooky AI Assistant
👋 Welcome to TechBooky AI Assistant

I can help with:
🔎 Tech News
🤖 AI Topics
💻 Gadgets
☁️ Cloud
✍️ Guest Posts
📢 Advertising
🔗 Backlinks
📩 Newsletter
  • AI Search
  • Cryptocurrency
  • Earnings
  • Enterprise
  • About TechBooky
  • Submit Article
  • Advertise With TechBooky
  • Contact Us
  • Data Intelligence
TechBooky
  • African
  • AI
  • Metaverse
  • Gadgets
  • Data Intelligence
  • AI Search
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
  • African
  • AI
  • Metaverse
  • Gadgets
  • Data Intelligence
  • AI Search
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
TechBooky
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Home Artificial Intelligence

OpenAI Tests Whether AI Can Pick Promising Drug Candidates

Fagbemi Daniel by Fagbemi Daniel
November 21, 2026
in Artificial Intelligence, Medical, Science
Share on FacebookShare on Twitter
Share this story

Send it to someone who should read it.

f Facebook X X in LinkedIn wa WhatsApp tg Telegram @ Email

In Brief
  • OpenAI has introduced MedChemBench, a new test of whether AI models can reason through the choices medicinal chemists make when looking for promising drug candidates.
  • Its results show substantial progress on reading molecular structures and explaining research evidence, but they do not demonstrate that an AI system has discovered a new...
  • The benchmark announced on 20 November consists of 99 problems drawn from 117 published papers and patents.

OpenAI has introduced MedChemBench, a new test of whether AI models can reason through the choices medicinal chemists make when looking for promising drug candidates. Its results show substantial progress on reading molecular structures and explaining research evidence, but they do not demonstrate that an AI system has discovered a new medicine.

The benchmark announced on 20 November consists of 99 problems drawn from 117 published papers and patents. It includes 761 distinct molecular structures. Rather than simply asking a model to name a compound, the test gives it information available at a particular stage of a research programme and asks it to interpret findings, compare candidates and predict properties.

OpenAI says GPT-6.2 Astra earned 84.5% of the available credit at its xhigh reasoning setting. GPT-6 Astra scored 83.3%, GPT-6.1 Sol 82.0% and GPT-5.6 Sol 58.2%. These are scores under OpenAI’s own benchmark conditions, not independent measurements of success in laboratories or clinical development. The differences should be read alongside the test’s methods and limitations.

The model’s performance was uneven. OpenAI says Astra earned 95.4% of available credit for reconstructing molecular structures at xhigh, yet only about half the credit for choosing compounds and predicting numerical properties. Those latter tasks are crucial because researchers have to balance competing goals. A molecule may act strongly against a biological target but be poorly absorbed or break down too quickly to become useful.

Also worth reading
OpenAI’s LifeVal Tests Whether AI Can Handle Everyday Tasks OpenAI Launches ChatGPT for Accounting With QuickBooks and Xero Plugins OpenAI Launches GPT-6.2 Astra and Sol After Earlier Cloud Sightings OpenAI Signs 457 MW AMD Compute Deal With TensorWave OpenAI Opens 50,000 New ChatGPT Grants for Academic Researchers OpenAI Releases Child Safety Image Classifier and New ChatGPT Warnings

A retrospective benchmark can show whether a model makes sense of historical evidence. It cannot establish that the model can choose the right experiment in an unfamiliar live project. OpenAI explicitly says its findings do not establish that the models can discover new drugs or improve laboratory decisions. Because the source papers were published, the company also cannot rule out prior exposure to some of the material during training.

The work fits into a wider push to bring AI into life sciences. TechBooky has covered OpenAI’s GPT-Rosalind research ambitions and its acquisition of Orchestra Bio, which focuses on the workflow around drug development. MedChemBench adds a more specific way to measure the reasoning a research assistant would need. It is not a substitute for experiments, safety studies or regulatory review.

The useful question is whether models can make reliable predictions on genuinely new compounds and improve decisions when chemists test them in the laboratory. Independent evaluation, transparent comparisons and results from prospective research programmes would provide stronger evidence than a score on published cases. For now, MedChemBench is a test of scientific reasoning, with the most consequential parts of candidate selection still proving difficult.

Related Reading

More contextual TechBooky stories selected from tags, categories and article context.

  • 492ae2fdf955e71a24bfda5422f950febeeec07f-2000x1125
    Anthropic Buys One-Person Drug Startup as Claude…
  • openaiorchestrabio
    OpenAI Buys Orchestra Bio to Bring AI Agents Into…
  • 1793899453_gpt-6_cyber
    OpenAI Unveils GPT-6 Cyber After Finding 81 Firefox Flaws
  • 6e50e1b4-3645-5a38-9c44-c3be0153d2e4
    OpenAI's LifeVal Tests Whether AI Can Handle Everyday Tasks
  • government-seo-card-16x9
    OpenAI Opens 50,000 New ChatGPT Grants for Academic…
  • 1776370209_gpt-rosalind
    OpenAI Unveils GPT-Rosalind, Aiming at Drug…
  • miles wang
    OpenAI Researcher's $2B Drug Discovery Plan Shows AI…
  • Multiply-Labs
    Multiply Labs Raises $75M To Bring Robots Into Drug…
Keep Reading Smarter

Search TechBooky with AI

Use TechBooky's AI Search to explore the context behind this story and related coverage across the site.

Try AI Search
More On This Topic
Artificial Intelligence Medical Science
Follow TechBooky

Follow TechBooky for more technology stories and newsroom updates.

f Facebook X X in LinkedIn ig Instagram wa WhatsApp

Tags: ai in medicinedrug discoverymedchembenchopenai
Fagbemi Daniel

Fagbemi Daniel

Search TechBooky
Open TechBooky AI Search Try the AI Assistant

BROWSE BY CATEGORIES

Receive top tech news directly in your inbox

subscription from
Loading

Freshly Squeezed

  • OpenAI Tests Whether AI Can Pick Promising Drug Candidates November 21, 2026
  • Anthropic Mathematician Claims Claude Helped Prove Riemann Hypothesis November 21, 2026
  • Nvidia Accounting Practices Under SEC Scrutiny, Reuters Says November 21, 2026
  • White House Names Kirsten Davies as Cyber Director Amid Outage Concerns November 20, 2026
  • Apple Job Listings Point to AI Agent That Can Work Across Apps November 20, 2026
  • Anthropic IPO Shares Give Back Early Gains as AI Stocks Sell Off November 20, 2026
  • Nigeria Selects Eight Startups for iDICE Growth Lab With Up to $100K Each November 20, 2026
  • AWS Lambda Doubles On-Demand Event Function Limit to 30 Minutes November 20, 2026
  • Alibaba AI Cloud Revenue Jumps 53% as September-Quarter Sales Reach $40.5B November 19, 2026
  • TSMC Tightens China AI Chip Orders as US Rules Take Effect, Reuters Reports November 19, 2026
  • First Circle Capital Closes $26M Fund to Back Africa’s Next Fintech Wave November 19, 2026
  • OpenAI Launches ChatGPT for Accounting With QuickBooks and Xero Plugins November 19, 2026

Browse Archives

November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Oct    

Quick Links

  • About TechBooky
  • Advertise With TechBooky
  • Contact us
  • Submit Article
  • Privacy Policy
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
  • AI
  • Data Intelligence
  • AI Search
  • African
  • Gadgets

© 2025 Designed By TechBooky Elite

Discover more from TechBooky

Subscribe now to keep reading and get access to the full archive.

Continue reading

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.